8 Recruiting Solid Tumor Clinical Trials in Texas
Explore active solid tumor research studies enrolling across Texas. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Solid Tumor Studies in Texas
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
📍 NEXT Oncology Dallas — Austin, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
📍 Mary Crowley Cancer Research — Dallas, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
📍 NEXT Oncology — San Antonio, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
📍 University of Texas Health Science Center at San Antonio — San Antonio, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 💊 Investigational Drug / Biologic
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔